跳至主要内容
临床试验/NCT03644251
NCT03644251终止不适用

FLO Injection for Discogenic Pain

Tissue Tech Inc.2 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2018年8月13日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
3
试验地点
2
主要终点
Change in patient back pain determined by visual analog scale

研究概览

简要总结

Discogenic pain is pain originating from a damaged vertebral disc and be caused by inflammation, dehydration of the nucleus pulposus, decreased disc height, annular tears and impaired mechanical function of the disc.Non-operative treatment may include traction, steroid therapy, methylene blue injection and ablative therapy. However, there are few high quality studies evaluating these treatments for reducing discogenic low back pain and most clinical trials failed to detect significant differences between treatments and placebo therapies. Hence, there remains an unmet clinical need.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • subject (male or female) is at least 18 to 70 years of age
  • diagnosed with single level discogenic back pain confirmed by MRI and positive discography per Spine Interventional Society Guidelines
  • Diagnosis of disc degeneration with Pfirrmann score of 1-3
  • Subject has failed at least six months of conservative care
  • Subject is symptomatic with axial lower back pain greater than lower limb pain at the intensity of >6/10 concordant or partially concordant
  • The subject is able to comply with all post-operative standard of care and follow instructions.

排除标准

  • Subjects has significant disc protrusion, severe lumbar spinal stenosis, spine tumor, severe disc degeneration, or Sacroiliac (SI) joint syndrome
  • Subject had previous surgery at the disc level
  • Patient has previously received injection of FLO within 3 months of screening
  • The subject is unable to comply with follow-up or not appropriate for inclusion based on investigator decision

结局指标

主要结局

Change in patient back pain determined by visual analog scale

时间窗: 3 months

0 to 100mm, 100mm worst pain

次要结局

  • Change in quality of life determined by SF-36(3 and 6 months)
  • Change in patient back pain determined by visual analog scale(6 months)
  • Change in Oswestry Disability Index(3 and 6 months)

研究者

发起方
Tissue Tech Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

FLO for Discogenic Pain | 临床试验